Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-810, for Treatment of Ornithine Transcarbamylase (OTC) Deficiency June 27, 2019 - NASDAQ Companies 0 » View More News for June 27, 2019